• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部无防腐剂制剂治疗青光眼:安全性和耐受性评价。

The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.

机构信息

1st and 3rd University Departments of Ophthalmology, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Department of Ophthalmology III, Quinze-Vingts Hospital, Paris, France;Quinze-Vingts Hospital, Paris, France; Inserm, ; RUPMC Univ Paris 06, Institut De La Vision; CNRS, ; CHNO Des Quinze-Vingts, INSERM-DHOS Paris, France; Department of Ophthalmology, Ambroise Paré Hospital, AP-HP, University of Versailles Saint-Quentin-en-Yvelines, Versailles, France.

出版信息

Expert Opin Drug Saf. 2021 Apr;20(4):453-466. doi: 10.1080/14740338.2021.1873947. Epub 2021 Jan 21.

DOI:10.1080/14740338.2021.1873947
PMID:33478284
Abstract

: Preservative-free (PF) medications represent a valuable treatment strategy in the lifelong management of glaucoma. By removing preservative toxicity, PF formulations provide tangible clinical benefits to glaucoma patients worldwide. They improve tolerability and adherence, leading to a positive impact in long-term intraocular pressure (IOP) control.: A critical review of the subject is provided, including selected evidence on the safety and tolerability of currently available topical PF formulations. Cumulative evidence confirms that topical PF medications are at least equally efficacious to their preserved equivalents. There is convincing short-term evidence for superior tolerability and safety of PF formulations compared to preserved medications. The long-term benefits and success of PF therapy requires further elucidation.: Successful stepwise administration of medical therapy for glaucoma remains elusive. There is a greater risk for ocular toxicity and therapy failure with preserved topical glaucoma therapy. Currently available and emerging PF therapy options potentially optimize lifelong stepwise glaucoma therapy and may enhance outcome. To avert complications from preservatives leading to poor adherence, ideally, future antiglaucoma therapy should become 100% PF. There are still key aspects of PF therapy that warrant further investigation.

摘要

无防腐剂(PF)药物是青光眼终身管理的一种有价值的治疗策略。通过消除防腐剂的毒性,PF 制剂为全球青光眼患者提供了切实的临床益处。它们提高了耐受性和依从性,对长期眼压(IOP)控制产生了积极影响。对这一主题进行了批判性的回顾,包括目前可用的局部 PF 制剂的安全性和耐受性的选择证据。累积的证据证实,局部 PF 药物与防腐剂等效物一样有效。与防腐剂相比,PF 制剂在短期和长期均具有更好的耐受性和安全性。PF 治疗的长期益处和成功需要进一步阐明。青光眼药物治疗的成功逐步实施仍然难以实现。保存的局部青光眼治疗有更大的眼部毒性和治疗失败的风险。目前可用和新兴的 PF 治疗选择可能优化青光眼的终身逐步治疗,并可能改善结果。为了避免防腐剂引起的并发症导致依从性差,理想情况下,未来的抗青光眼治疗应 100%采用 PF。PF 治疗仍有一些关键方面需要进一步研究。

相似文献

1
The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.局部无防腐剂制剂治疗青光眼:安全性和耐受性评价。
Expert Opin Drug Saf. 2021 Apr;20(4):453-466. doi: 10.1080/14740338.2021.1873947. Epub 2021 Jan 21.
2
Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review.当前和新兴的青光眼固定联合疗法:安全性和耐受性评价。
Expert Opin Drug Saf. 2020 Nov;19(11):1445-1460. doi: 10.1080/14740338.2020.1826928. Epub 2020 Sep 29.
3
24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.在使用含防腐剂的拉坦前列素单药治疗控制不佳的开角型青光眼患者中,单独使用无防腐剂的他氟前列素以及联合使用无防腐剂的多佐胺/噻吗洛尔固定复方制剂的24小时疗效和眼表健康情况
Adv Ther. 2017 Jan;34(1):221-235. doi: 10.1007/s12325-016-0448-9. Epub 2016 Dec 2.
4
Preservatives in glaucoma medication.青光眼药物中的防腐剂。
Br J Ophthalmol. 2018 Nov;102(11):1497-1503. doi: 10.1136/bjophthalmol-2017-311544. Epub 2018 Jul 4.
5
Topical preservative-free ophthalmic treatments: an unmet clinical need.局部无防腐剂的眼科治疗:未满足的临床需求。
Expert Opin Drug Deliv. 2021 Jun;18(6):655-672. doi: 10.1080/17425247.2021.1860014. Epub 2020 Dec 16.
6
Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.用于青光眼和高眼压症的固定复方降眼压疗法:临床实践中的优势
Expert Opin Pharmacother. 2014 Aug;15(12):1737-47. doi: 10.1517/14656566.2014.936850. Epub 2014 Jul 5.
7
Preservative-free treatment in glaucoma: who, when, and why.青光眼的无防腐剂治疗:对象、时机及原因
Eur J Ophthalmol. 2013 Jul-Aug;23(4):518-25. doi: 10.5301/ejo.5000270. Epub 2013 Mar 7.
8
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension.探讨前列腺素类似物滴眼剂在青光眼和高眼压症中的安全性和耐受性。
Expert Opin Drug Saf. 2022 Apr;21(4):525-539. doi: 10.1080/14740338.2022.1996560. Epub 2021 Oct 29.
9
Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.无防腐剂前列腺素类似物和前列腺素/噻吗洛尔固定组合治疗青光眼:疗效、安全性和潜在优势。
Drugs. 2018 Jan;78(1):39-64. doi: 10.1007/s40265-017-0843-9.
10
IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.在患有眼高压或青光眼的患者中,无防腐剂他氟前列素 0.0015% 的降眼压效果和耐受性。
Curr Med Res Opin. 2010 Aug;26(8):1905-13. doi: 10.1185/03007995.2010.492030.

引用本文的文献

1
Association Between Preserved Glaucoma Eye Drops Exposure and Glaucoma Surgery Occurrence: A Nationwide 10-Year Outcome Study.青光眼滴眼液持续使用与青光眼手术发生率之间的关联:一项全国性10年结局研究。
Ophthalmol Ther. 2025 Aug 22. doi: 10.1007/s40123-025-01203-1.
2
Should we reconsider first-line treatments for glaucoma in the setting of meibomian gland dysfunction and ocular surface disease: Glaucoma treatments and its effects.在睑板腺功能障碍和眼表疾病背景下,我们是否应重新考虑青光眼的一线治疗:青光眼治疗及其效果。
Front Ophthalmol (Lausanne). 2023 Feb 6;3:958955. doi: 10.3389/fopht.2023.958955. eCollection 2023.
3
The PRAMOS Study: PRostaglandin Analogues Monotherapy-Awareness Survey on Ocular Surface Involvement.
PRAMOS研究:前列腺素类似物单药治疗——眼表受累情况的认知调查
Ophthalmol Ther. 2024 Jun;13(6):1537-1551. doi: 10.1007/s40123-024-00936-9. Epub 2024 Apr 8.
4
Impact of Latanoprost Antiglaucoma Eyedrops and Their Excipients on Toxicity and Healing Characteristics in the Ex Vivo Eye Irritation Test System.拉坦前列素抗青光眼滴眼液及其辅料在离体眼刺激试验系统中对毒性和愈合特性的影响
Ophthalmol Ther. 2023 Oct;12(5):2641-2655. doi: 10.1007/s40123-023-00769-y. Epub 2023 Jul 24.
5
Adherence and Persistence to Medical Therapy in Glaucoma: An Overview.青光眼治疗的依从性和持续性:综述
Ophthalmol Ther. 2023 Oct;12(5):2227-2240. doi: 10.1007/s40123-023-00730-z. Epub 2023 Jun 14.
6
Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial.从含防腐剂的环孢素 0.1%到不含防腐剂的环孢素 0.1%增强型三联青光眼治疗方案的转换:对眼表疾病的影响——一项随机对照试验。
Eye (Lond). 2023 Dec;37(17):3666-3674. doi: 10.1038/s41433-023-02578-w. Epub 2023 May 23.
7
Glaucoma and Ocular Surface Disease: More than Meets the Eye.青光眼与眼表疾病:不止于所见
Clin Ophthalmol. 2022 Nov 4;16:3641-3649. doi: 10.2147/OPTH.S388886. eCollection 2022.
8
Is it time for a moratorium on the use of benzalkonium chloride in eyedrops?是时候暂停在滴眼液中使用苯扎氯铵了吗?
Br J Clin Pharmacol. 2022 Sep;88(9):3947-3949. doi: 10.1111/bcp.15359. Epub 2022 May 8.
9
Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.比较青光眼患者中保存型和无保存剂型拉坦前列素的眼表评估和依从性:一项平行分组随机试验。
Sci Rep. 2021 Jul 22;11(1):14971. doi: 10.1038/s41598-021-94574-x.